Top-News

Altimmune Aktie News

Aktie
WKN:  A2N5Z6 ISIN:  US02155H2004 US-Symbol:  ALT Branche:  Biotechnologie Land:  USA
4,561 €
+0,007 €
+0,15%
08:12:43 Uhr
Depot/Watchlist
Marktkapitalisierung *
255,01 Mio. €
Streubesitz
63,02%
KGV
-5,42
Dividende
54,21 €
Dividendenrendite
1.227,54%
Index-Zuordnung
-

Altimmune News

22.09.25 - PR Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
19.09.25 - PR Newswire
October 6, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT
October 6, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT PR Newswire
18.09.25 - PR Newswire
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT PR Newswire
18.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT PR Newswire
18.09.25 - PR Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT PR Newswire
18.09.25 - PR Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
16.09.25 - PR Newswire
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT PR Newswire
16.09.25 - PR Newswire
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT PR Newswire
15.09.25 - PR Newswire
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT PR Newswire
13.09.25 - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune PR Newswire
13.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT PR Newswire
12.09.25 - PR Newswire
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT PR Newswire
11.09.25 - PR Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit PR Newswire
11.09.25 - PR Newswire
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT PR Newswire
09.09.25 - PR Newswire
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT PR Newswire
08.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT PR Newswire
08.09.25 - PR Newswire
The Gross Law Firm Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
The Gross Law Firm Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT PR Newswire
06.09.25 - PR Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit PR Newswire
06.09.25 - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune PR Newswire
05.09.25 - PR Newswire
Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT PR Newswire

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »